<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="836">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00193908</nctid>
  <trial_identification>
    <studytitle>Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream</studytitle>
    <scientifictitle>A Paired Double Blind Randomised Comparison of Cavilon(TM) Durable Barrier Cream(TM)[CDBC] to 10% Glycerine ("Sorbolene") Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TROG 04.01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cavilon (TM) Durable Barrier Cream
Treatment: drugs - Sorbolene
Treatment: other - Radiotherapy

Experimental: 1 - 

Experimental: 2 - 


Treatment: drugs: Cavilon (TM) Durable Barrier Cream
Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.

Treatment: drugs: Sorbolene
Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation

Treatment: other: Radiotherapy
Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency of moist desquamation (grade 3) acute skin reaction scored as worst reaction within allocated skin care area</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Skin toxicity area under the curve (AUC) being sum of maximum skin reaction per week over 12 weeks</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ages 18 or more years

          -  Post total mastectomy

          -  Planned dose at least 45 Gy in 25 fractions

          -  ECOG 0-2

          -  Able to attend weekly during treatment for review and photo and for up to 6 weeks
             after radiotherapy

          -  Patients capable of childbearing using adequate contraception

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous radiotherapy to the chest wall to be treated

          -  Macroscopic cutaneous involvement by malignancy at time of radiotherapy

          -  Known allergy to product contents

          -  Patients who are pregnant or lactating.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>333</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Calvary Mater Newcastle - Newcastle</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Westmead Hospital - Wentworthville</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>Royal Brisbane Hospital - Herston</hospital>
    <hospital>Mater QRI - South Brisbane</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Andrew Love Cancer Care Centre, Geelong Hospital - Geelong</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>1871 - Liverpool</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode> - Wollongong</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>3M</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study has patients using two different moisturising creams during radiation therapy
      after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may
      be reduced by the Cavilon cream compared to sorbolene.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00193908</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Graham</name>
      <address>St George Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>